Xarelto Lawsuit Plaintiff Requests $4.35 Million In Lawsuit Claiming Dangerous Bleeding Episode

March 28, 2016 – – BloodThinnerHelp.com reports on another lawsuit that has been filed against Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation), and multiple other defendants, regarding new-generation anticoagulant Xarelto. The plaintiff filing suit claims that the anticoagulant caused him to suffer from a sudden and uncontrollable bleeding episode.

The man’s complaint was transferred and consolidated with all federally-filed Xarelto lawsuits by the U.S. Judicial Panel on Multidistrict Litigation forming MDL No. 2592 in Eastern Louisiana. These lawsuits are being presided over by The Honorable Judge Eldon E. Fallon, who has currently ordered bellwether trial preparations and tentatively scheduled bellwether trial dates for early 2017.

Among the thousands of Xarelto lawsuits, this one is significant because it involves 90-counts and the plaintiff filing it is requesting $4.35 million in compensation. Court documents show that the plaintiff claims that Bayer and Janssen misleadingly marketed Xarelto as a safe and effective drug option for patients hoping to reduce their risk of strokes, and also that the defendants failed to adequately warn the public of potentially dangerous side effects that he now links to the drug.

Additionally, the plaintiff claims that these manufacturers were likely aware that the anticoagulant may cause a heightened risk of bleeding episodes for patients using it. Clinical studies conducted on the drug, the plaintiff notes, help to support this argument. He alleges that if the defendants were aware of these possible dangers, they acted with negligence by doing nothing to protect the public with this valuable information. The plaintiff stated, “Defendants use the results of the Rocket AF study, the Record studies, and the Einstein studies to promote Xarelto in their promotional materials, including the Xarelto website, which tout the positive results of those studies. However, defendants’ promotional materials fail to similarly highlight the increased risk of gastrointestinal bleeding and bleeding that required transfusion among other serious bleeding concerns.”

The U.S. Food and Drug Administration approved Xarelto in 2011 to treat patients with atrial fibrillation, pulmonary embolism, and deep vein thrombosis as well as those recovering from hip and knee replacement surgeries. As a new-generation blood thinner, it provided patients with freedoms that more traditional blood thinners had not been able to, and was therefore initially popular. Today, however, lawsuits surrounding the drug continue to increase in number. The Eastern Louisiana MDL is made up of over 2,800 complaints against the drug, while a group of more than 600 others was consolidated to form a mass tort program in Philadelphia, Pennsylvania by the Court of Common Pleas.

As lawsuit numbers are predicted by many to continue to rise, Attorney Joseph Osborne is working to assist patients who took Xarelto and who suffered from health problems that they attribute to the drug. He wants to ensure that these individuals will be provided with the opportunity to fully investigate their legal rights. Affected parties may be entitled to significant compensation attained through legal action. To assist those looking to pursue justice in the matter, Attorney Osborne is offering complimentary consultations for affected individuals.

To request further Xarelto lawsuit information, or to ask questions, please contact Attorney Osborne by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60008909